Pilot Randomized Controlled Trial of a Standard Versus a Modified Low-Phosphorus Diet in Hemodialysis Patients

Fiona N. Byrne1,2,3, Barbara A. Gillman4,5, Mairead Kiely6, Brendan Palme3,7, Frances Shiely3,7, Patricia M. Kearney7, Joyce Earlie8, Maria B. Bowles9,10, Fiona M. Keohane1,2, Pauline P. Connolly11,12, Sarah Wade13,14, Theresa A. Rennick15,16, Bernice L. Moore17,18, Oonagh N. Smith17,18, Celene M. Sands19, Orla Slevin20,21, Denise C. McCarthy22, Karina M. Brennan23, Halóg Mellett24,25, Darren Daly3,7, Eoin Bergin16, Liam F. Casserly10, Peter J. Conlon18, Kieran Hannan12, John Holian14, David W. Lappin21, Yvonne M. O’Meara5, George J. Mellotte25, Donal Reddan21, Alan Watson14 and Joseph Eustace2,3

1Department of Nutrition and Dietetics, Cork University Hospital, Cork, Ireland; 2Department of Renal Medicine, Cork University Hospital, Cork, Ireland; 3School of Food and Nutritional Sciences University College Cork, Cork, Ireland; 4Health Research Board, Clinical Research Facility, Cork, Ireland; 5Health Research Board, Clinical Research Facility, Dublin, Ireland; 6Department of Renal Medicine, Mater Misericordiae University Hospital, Dublin, Ireland; 7School of Food and Nutritional Sciences University College Cork, Cork, Ireland; 8Beacon Renal, Tallaght, Dublin, Ireland; 9Department of Nutrition and Dietetics, University Hospital Limerick, Limerick, Ireland; 10Departments of Nephrology and Internal Medicine, University Hospital Limerick, Limerick, Ireland; 11Department of Nutrition and Dietetics, Cavan General Hospital, Cavan, Ireland; 12Department of Medicine, Cavan General Hospital, Cavan, Ireland; 13Department of Nutrition and Dietetics, St. Vincent’s University Hospital Dublin, Dublin, Ireland; 14Department of Nephrology, St. Vincent’s University Hospital Dublin, Dublin, Ireland; 15Department of Nutrition and Dietetics, Galway University Hospitals, Galway, Ireland; 16Department of Nephrology, Midland Regional Hospital, Tullamore, Ireland; 17Department of Nutrition and Dietetics, Beaumont Hospital, Dublin, Ireland; 18Beaumont Hospital Kidney Center, Beaumont Hospital, Dublin, Ireland; 19Department of Nutrition and Dietetics, Misericordiae University Hospital, Dublin, Ireland; 20Northern Cross Dialysis Center, Fresenius Medical Care, Dublin, Ireland; 21Beacon Renal Drogheda, Drogheda, Ireland; 22Department of Nutrition and Dietetics, Tallaght University Hospital, Dublin, Ireland; and 23Department of Nephrology, Tallaght University Hospital, Dublin, Ireland

Introduction: The standard low-phosphorus diet restricts pulses, nuts, and whole grains and other high phosphorus foods to control hyperphosphatemia. We conducted a randomized controlled trial to evaluate the effectiveness, safety, and tolerability of the modified diet, which introduced some pulses and nuts, increased the use of whole grains, increased focus on the avoidance of phosphate additives, and introduced the prescription of low-biological-value protein such as bread.

Methods: We conducted a multicenter, pragmatic, parallel-arm, open-label, randomized controlled trial of modified versus standard diet in 74 adults on hemodialysis with hyperphosphatemia over 1 month. Biochemistry was assessed using monthly laboratory tests. Dietary intake was assessed using a 2-day record of weighed intake of food, and tolerability was assessed using a patient questionnaire.

Results: There was no significant difference in the change in serum phosphate between the standard and modified diets. Although total dietary phosphorus intake was similar, phytate-bound phosphorus, found in pulses, nuts, and whole grains, was significantly higher in the modified diet (P < 0.001). Dietary fiber intake was also significantly higher (P < 0.003), as was the percentage of patients reporting an increase in bowel movements while following the modified diet (P = 0.008). There was no significant difference in the change in serum potassium or in reported protein intake between the 2 diets. Both diets were similarly well tolerated.

Conclusion: The modified low phosphorus diet was well tolerated and was associated with similar phosphate and potassium control but with a wider food choice and greater fiber intake than the standard diet.

Kidney Int Rep (2020) 5, 1945–1955; https://doi.org/10.1016/j.ekir.2020.08.008

KEYWORDS: diet; hyperphosphatemia; phosphates; potassium; renal dialysis

© 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

See Commentary on Page 1845

Hyperphosphatemia is common in end-stage kidney disease (ESKD) and is associated with excess morbidity and mortality. Dietary phosphorus...
Avoidance of plant protein in the form of whole grains, pulses, and nuts, and by avoiding phosphate additives has been shown to improve phosphate content (e.g., dairy, whole grains, unsalted peanuts). Therefore, not as available for absorption. Avoiding phosphate additives carries an obligatory protein load, thus avoiding overprescription of protein that would be required for the synthesized protein (e.g., fish has been reduced to 25 g of fish per 7 g of protein exchange). Two portions of fruit and 2 portions of vegetable were counted as 4 g of protein. Beef has lowest P:protein ratio (7 mg/g), while oily fish having the highest ratio (11 mg/g). However, the consensus reached was not to focus on the ratio in this food group, and to broadly follow healthy eating guidelines to encourage variety, including consumption of fish twice a week. Fish is a good source of omega-3 fatty acids, which are beneficial for heart health.

Emerging opinion supports the introduction of more plant protein in the form of whole grains, pulses, and nuts, and by avoiding phosphate additives. Emerging evidence supports the introduction of more plant protein in the form of whole grains, pulses, and nuts, and by avoiding phosphate additives. Based on this emerging evidence, we revised the Irish national low phosphorus diet sheet. We conducted a multicenter, pragmatic, parallel-arm, open-label, randomized controlled trial (RCT) of the efficacy, safety and tolerability of the modified diet in order to guide implementation.

The primary study objective was to determine whether the modified low phosphorus diet was comparable to current management in reducing serum phosphate levels in hemodialysis (HD) patients. The secondary objectives were to determine self-reported tolerability, safety in respect to hyperkalemia, and the nutritional composition, specifically the phosphorus, the phytate bound phosphorus, and the fiber content of the modified diet.

**Materials and Methods**

The protocol for this national, multicenter, pragmatic, parallel-arm, open-label RCT was developed according to the SPIRIT statement and conducted in accordance with the Declaration of Helsinki. The trial was registered at ClinicalTrials.gov: NCT03146923. Ethical approval was obtained from the Clinical Research Ethics Committee of the Cork Teaching Hospitals ECM 4(I) 10/01/17 and at each center where the trial took place. All participants provided written informed consent.

Practicing registered renal dietitians from all dialysis units in Ireland were invited to participate in the trial. A total of 15 dietitians from 9 university hospital dialysis units and 4 satellite dialysis units agreed to participate. Training, including Good Clinical Practice, general research training and methodology specific to the trial, was provided at a 2-day training program held by the Health Research Board Clinical Research Facility Cork (HRB CRF-C) at University College Cork in January 2017.

Inclusion criteria: patients ≥18 years; a self-reported urine output of <400 ml/d; treatment with hemodialysis for >3 months; and an average serum phosphate of >5 mg/dl over the last 3 months. Exclusion criteria were hyperkalemia (predialysis serum potassium of >6 mEq/l in the month preceding the trial); parathyroidectomy; and an abnormal corrected serum calcium level in the preceding month. Patients with acute concurrent illness who required hospitalization in the 2 weeks prior to recruitment were also excluded. Patients with abnormal serum corrected calcium were also excluded, as this may have warranted intervention during the trial.

All participants were receiving standard care, which involved one-to-one counseling with the patient and the patient’s relevant family members or carers/caregivers regarding a diet that provides approximately 1000 mg phosphorus per day and is based on the national diet sheet Eating Well with Kidney Disease. It includes the following main components: restricting protein intake to requirements of 1 to 1.2 g/kg ideal body weight (IBW); aiming for 70% high biological

Table 1. Summary of changes in modified diet sheet

| Nutrient-based recommendations | Food-based recommendations |
|-------------------------------|----------------------------|
| Two of the daily allowances of high biological value protein exchanges (7 g protein exchange) are replaced with plant-based vegetable protein exchanges (e.g. replace 50 g of meat with 100 g of pulses and 25 g of unsalted peanuts). Whole grain breads and cereals are encouraged. | Focus on more accurate protein prescription of 1.1 g of protein/kg ideal body weight, thus avoiding overprescription of protein that carries an obligatory protein load, and include some focus on phosphorus-to-protein ratio. |

| Inclusion of foods with reduced phosphorus bioavailability due to phytate content | Bread, cereals, and potatoes have been included in prescribed daily protein allowances. |
|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Phosphorus-to-protein ratio: Beef has lowest P:protein ratio (7 mg/g), with oily fish having the highest ratio (11 mg/g). However, the consensus reached was not to focus on the ratio in this food group, and to broadly follow healthy eating guidelines to encourage variety, including consumption of fish twice a week. Dairy products are restricted to 1 portion per day P:protein ratio 20–30 mg/g. Egg whites, which have an extremely low ratio 1.1 mg P/g protein, are included | Two portions of fruit and 2 portions of vegetable were counted as 4 g of protein.|
| Check for phosphate E numbers E338, E339, E340, E341, E343, E450, E451, E452, and E541. We also advised to check for “phos” on ingredient lists, giving examples that we commonly encountered on labels, such as diphasphate, sodium polyphosphate, and calcium triphosphate. | Check for phosphate E numbers E338, E339, E340, E341, E343, E450, E451, E452, and E541. We also advised to check for “phos” on ingredient lists, giving examples that we commonly encountered on labels, such as diphasphate, sodium polyphosphate, and calcium triphosphate. |

**P. phosphorus.**
value (HBV); restricting dairy intake (1–1.5 portions per day equivalent to 200–300 ml of milk); avoiding foods high in phosphate; and avoiding foods with phosphate additives.

The evidence base for the revised dietary phosphorus recommendations and their translation into dietary advice, as well as the diet sheet, have been described in detail elsewhere. Table 1 summarizes the main changes made to the modified diet. We attempted to blind patients by avoiding the use of terminology such as “old” and “new” and by retyping the standard diet sheet to match the font, layout, and introduction of the modified diet sheet. Both diet sheets were approved by the National Adult Literacy Agency (NALA).

From 1 week before the trial began, relevant medications, dialysis times, or dialysate were not changed unless approved by the nephrologists. Prior to randomization, all patients received an individual anthropometric and dietary assessment by a registered renal dietitian. Following randomization and baseline blood tests, patients randomized to standard care were re-educated regarding their diet and provided with the standard diet sheet. Patients following the modified diet were educated and provided with their diet sheet, product samples of pulses and nuts, a recipe booklet, and a shopping card of phosphate additives to look out for. Both groups were given weighing scales to help with portion control, especially for high-protein foods such as meat and fish. Participants were visited on the second and last weeks of the trial to remind them of the importance of adhering to the intervention for the month.

The trial started with education of the participants regarding their assigned diet, following their routine monthly dialysis laboratory tests, which served as baseline blood tests, and ended at the following month’s routine set of laboratory tests, which served as the end of intervention blood tests. In units that had access to a suitable freezer, an additional sample was taken to assess FGF23.

In the days leading up to the end of intervention blood tests, patients kept a 2-day record of weighed intake, including 1 dialysis day and 1 nondialysis day, to assess dietary changes. The days were nonconsecutive days. Participants were educated on how to record the weighed intake and were asked to collect labels so that the researcher could more accurately capture foods that had phosphate additives. If the weight of the food was not available, we used the hierarchical approach to quantification previously described. Nutrient analysis was carried out using Nutritics Software. A bespoke additional data field was added to the software to allow the dietitian to tag foods with a significant phytate content, including pulses, nuts and wholemeal/wholegrain breads, cereals, pasta, and rice. Foods identified as having a phosphate additive were also marked on data entry using a second added field. Nutritics contains multiple nutrient databases; however, we restricted the databases used to McCance and Widdowson’s composition of foods integrated dataset, the USDA Food Composition Databases, and the Irish food composition databases. To standardize food coding practice and data entry, the coordinating center provided units with a list of standard food codes for foods generated from the diet sheets, and for any new recipes or new food codes required. Food code queries were answered by the coordinating center, collated, and shared with all centers. Further details are described in the standard operating procedure available online as an Open Science Framework (OSF) project (https://doi.org/10.17605/OSF.IO/FSK8T).

Participants were also asked to complete a tolerance questionnaire. When the trial concluded, each patient was advised to go back to following the standard diet.

There are no core outcome sets for ESKD. Based on prior trials and audit of phosphate data, it was calculated that we would require a total of 56 participants in each arm, using an independent-sample t test with a 1:1 allocation ratio, a 2-sided type I error of 0.05, a power of 90%, and an effect size of 0.73. Power remained at 80% even with 64 analyzable participants (32 in each arm), all else being equal.

The specific randomization list was designed by an independent trial statistician, and participants were randomly assigned to either the control or intervention group with a 1:1 allocation as per a computer-generated randomization schedule, stratified by site and by baseline phosphate, using permuted blocks of random sizes and allocated using a sequentially numbered, opaque, sealed envelope approach. The block sizes were not disclosed so as to ensure concealment. The allocation of patients to treatment arms was revealed after the patient was consented. Patients were withdrawn from the study if they had a confirmed serum potassium of ≥6.3 mEq/l. Statistical analysis was performed by staff at the HRB CRF-C. Categorical data were described as counts and percentages, and continuous variables were summarized using medians and minimum and maximum values. The study outcomes were explored using simple or multiple linear regression. We report estimates, 95% confidence intervals, and corresponding P values. Analysis of categorical patient survey data was performed using a Fisher exact test. Analyses were done on an intention-to-treat basis. All analyses were conducted using the R Project for Statistical Computing version 3.6 (R Core Team, Vienna,
Figure 1 describes the study flow. Of the 74 participants recruited, 52 were recruited in March 2017, and 22 were recruited in May 2017. In all, 39 participants were randomized to the standard arm and 35 to the modified diet arm. The data presented represent the intention-to-treat analysis of all patients, excluding instances in which an endpoint sample was not recorded. Table 2 summarizes the baseline characteristic of the trial population. The study population was 69% male and predominantly of white ethnicity. There were more patients with diabetes randomized to the modified arm (n = 17) than to the standard arm (n = 10).

Table 3 describes the prespecified trial outcome measures. There was no significant difference in serum phosphate or serum potassium after 1 month between the standard and modified diets (Table 3, Figure 2). Significant variability in serum potassium and phosphate was observed in both groups, as demonstrated in Figure 3. Serum bicarbonate levels

---

**RESULTS**

Figure 1 describes the study flow. Of the 74 participants recruited, 52 were recruited in March 2017, and 22 were recruited in May 2017. In all, 39 participants were randomized to the standard arm and 35 to the modified diet arm. The data presented represent the intention-to-treat analysis of all patients, excluding instances in which an endpoint sample was not recorded. Table 2 summarizes the baseline characteristic of the trial population. The study population was 69% male and predominantly of white ethnicity. There were more patients with diabetes randomized to the modified arm (n = 17) than to the standard arm (n = 10).

Table 3 describes the prespecified trial outcome measures. There was no significant difference in serum phosphate or serum potassium after 1 month between the standard and modified diets (Table 3, Figure 2). Significant variability in serum potassium and phosphate was observed in both groups, as demonstrated in Figure 3. Serum bicarbonate levels

---

**Table 2. Demographics and medications**

| Variable                                      | Standard diet (n = 39) | Modified diet (n = 35) |
|-----------------------------------------------|-----------------------|------------------------|
|                                               | n (%)                 | Median (Min, max)      | n (%) | Median (Min, max)      |
| Male sex                                      | 26 (66.7%)            | 59.9 (28.7, 88.3)      | 25 (71.4%) | 61.0 (29.3, 84.9)  |
| White ethnicity                               | 38 (97.4%)            | 81.5 (57.5, 149.1)     | 33 (94.3%) | 80.0 (49, 132)     |
| Diabetes as a comorbidity                     | 10 (25.6%)            | 80.9 (58, 150)         | 17 (48.6%) | 79.8 (49, 134)   |
| Diabetes as a cause of ESKD                   | 8 (20.5%)             | 71.2 (57.3, 86.2)      | 14 (40%)  | 67.7 (49, 83.7)   |
| Age, yr                                       |                       | 59.9 (28.7, 88.3)      | 61.0 (29.3, 84.9)  |
| Baseline dry weight, kg                       | 81.5 (57.5, 149.1)    | 80.9 (58, 150)         | 79.8 (49, 134)   |
| End of intervention dry weight, kg            |                       | 1.70 (1.51, 1.86)      | 1.67 (1, 1.87)   |
| BMI, kg/m²                                     | 28.4 (21.8, 48.9)     | 71.2 (57.3, 86.2)      | 27.7 (17.9, 48.4) |
| IBW, kg                                       | 80.0 (49, 132)        | 79.8 (49, 134)         | 74.5 (53.9, 92.1) |
| Recommended protein intake 1.1 gKg IBW        | 78.3 (83, 94.8)       | 79.8 (49, 134)         | 74.5 (53.9, 92.1) |
| Baseline serum phosphate, mg/dl               | 5.92 (3.53, 12.1)     | 6.13 (3.90, 10.2)      | 70 (58, 83)      |
| Baseline urea reduction ratio, %              | 71.8 (40.4, 84)       | 71.8 (40.4, 84)        | 70 (58, 83)      |
| Baseline bicarbonate, mEq/l                   | 22 (18, 26)           | 22 (18, 26)            | 23.5 (17.6, 29.6) |

**Medications**

| Vitamin D native IU                           | 11 (28%)              | 800 (343, 7142.9)     | 10 (29%) | 800 (200, 5714) |
| Alfacalcidol, µg                              | 23 (59%)              | 0.5 (0.11, 1.0)       | 20 (57%) | 0.37 (0.25, 1.0) |
| Paricalcitol oral, µg                         | 4 (10%)               | 2 (1.43, 4)           | 7 (20%)  | 1.71 (1, 2)     |
| Paricalcitol i.v., µg                         | 3 (8%)                | 1.07 (0.86, 2.14)     | 1 (3%)   | 2.14 NA         |
| Calcitriol, µg                                | 0 (0%)                | NA                    | 1 (3%)   | 12.5 NA         |
| Cinacalcet, mg                                | 5 (13%)               | 60 (30, 120)          | 6 (17%)  | 60 (30, 120)    |

**Binders**

| Sevelamer carbonate, mg                       | 14 (36%)              | 7200 (800, 9600)      | 12 (35%) | 4800 (1600, 14400) |
| Sevelamer hydrochloride, mg                  | 9 (23%)               | 4800 (1600, 7200)     | 8 (24%)  | 4800 (2400, 7200) |
| Calcium carbonate, mg                        | 4 (10%)               | 1500 (1250, 3000)     | 1 (3%)   | 1500 (1500, 1500) |
| Calcium acetate, mg                          | 12 (31%)              | 2500 (1000, 4000)     | 13 (38%) | 3000 (1000, 3000) |
| Calcium acetate magnesium carbonate, mg      | 1 (3%)                | 870 (NA)              | 0 (0%)   | NA               |
| Lanthanum carbonate, mg                      | 4 (10%)               | 2025 (1500, 3000)     | 2 (6%)   | 3500 (3000, 4000) |
| Sucroferric oxyhydroxide, mg                 | 3 (8%)                | 1500 (3, 1500)        | 5 (15%)  | 1500 (1500, 1500) |
| Aloxaps, mg                                  | 1 (3%)                | 1425 (NA)             | 0 (0%)   | NA               |

BMI, body mass index; ESKD, end-stage kidney disease; IBW, ideal body weight; NA, not applicable.

*Number of patients on the medication/binder by trial arm.

Median intake of patients on the medication/binder by trial arm, with associated minimum and maximum amounts.
were not significantly different in participants following the standard and participants following the modified diet at the end of the intervention ($P = 0.493$). One patient from either arm was withdrawn because of hyperkalemia; withdrawal of the participant assigned to the modified diet occurred at the baseline tests stage, prior to the education step and initiation of the modified diet.

On the standard diet arm, there were 3 deviations: 1 change to medication, 1 change to dialysis times, and a new catheter. On the modified arm, there were also 3 deviations: 1 change to medication, 1 change to dialysis times, and 1 change of dialysate.

Table 4 describes mean dietary intake on the dialysis day and the nondialysis day, as assessed by the 2-day weighed intake record at the end of the intervention period. Nutrient intakes were not significantly different between the 2 groups, with the exception of dietary fiber. Although total dietary phosphorus was similar, there were significant differences between the standard and modified diets when we divided the food sources of dietary phosphorus into foods in which phosphorus is or is not bound by phytate (Figure 4). Combining dialysis and nondialysis days, participants following the modified diet consumed more fiber and phytate bound phosphorus than those assigned the standard diet (mean = 4.65 g, 95% confidence interval = 1.68–7.61,

![Figure 2. Serum phosphate and potassium. Box plot A shows phosphate at 2 time points, baseline and end of intervention, with the standard diet in the darker shade and the modified diet shown in the lighter shade. The box represents the interquartile range, with the thick line in the box representing median values. In both arms of the trial (standard and modified), there was a small decrease in serum phosphate, likely reflecting education; however, no statistically significant differences were observed for the primary outcome of serum phosphate and potassium between the standard and modified diet. A similar pattern was seen for potassium.](image-url)

| Variable                                | n$^a$ | Change from baseline | Analyses to determine impact of diet$^b$ |
|-----------------------------------------|-------|----------------------|----------------------------------------|
|                                         |       | Standard Modified    | Estimate $^c$ $\bar{P}$ value $^d$ 95% CI |
| Primary outcome                         |       |                      |                                        |
| Serum phosphate, mg/dl, mean (SD)       | 38    | 34                   | $-0.336$ ($1.536$) $-0.296$ ($1.456$) | 0.133 0.69 $-0.537$ 0.803 |
| Secondary outcomes                      |       |                      |                                        |
| Total phosphorus intake, mg, mean (SD)  | 30    | 30                   | NA NA                                  | 77.5 0.343 $-84.7$ 239.7 |
| Phytate-bound phosphorus intake, mg, mean (SD) | 30 | 30 | NA NA | 207.8 $< 0.001$ 130.4 286.2 |
| Fiber intake, g, mean (SD)              | 30    | 30                   | NA NA                                  | 4.65 $< 0.003$ 1.68 7.61 |
| Intact PTH, pg/ml, median (IQR)$^4$    | 35    | 31                   | $-3.9$ ($20.7$) $-0.7$ ($25.0$) $0.995^c$ 0.968 0.780 1.270 |
| Exploratory endpoint                    |       |                      |                                        |
| C-terminal FGF23, RU/ml, median (IQR)$^4$ | 15  | 12                   | $-50$ ($4065$) $-105$ ($2570$) $0.98^c$ 0.912 0.681 1.141 |
| Safety endpoints                        |       |                      |                                        |
| Serum potassium, mEq/l, mean (SD)       | 39    | 34                   | $0.08$ ($0.60$) $0.01$ ($0.69$) $-0.097$ 0.422 $-0.335$ 0.142 |

CI, confidence interval; FGF, fibroblast growth factor; IQR, interquartile range; NA, not applicable; PTH, parathyroid hormone.

$^a$Number of complete data points available for analysis.
$^b$Serum phosphate and serum potassium were described by multiple linear regression of endpoint explained by covariates of baseline and diet. Intact PTH and FGF23 were described by multiple linear regression of log(endpoint) explained by covariates of log(baseline) and diet. Total phosphorus intake, phytate-bound intake, and fiber intake were described by simple linear regression of intake explained by diet.

$^c$The standard diet was set as the reference level for all linear models.

$^d$For log–log transformations, the estimated effect of a change in diet, from standard to modified, is to change intact PTH by a factor of 0.995 and FGF23 by a factor of 0.98, respectively.
Reported protein intake was less than the target prescribed in both arms but was not significantly different between arms (Table 4). Mean (SD) reported energy intake (kcals) divided by the basal metabolic rate (BMR) calculated using the Schofield equation was 0.97 (0.32) and 0.86 (0.35) on the dialysis day and nondialysis day, respectively, in participants following the standard diet. It was 0.88 (0.21) and 0.84 (0.25) on the dialysis day and nondialysis day, respectively, in those following the modified diet. There were no significant differences in weight or predialysis urea between the 2 groups. Overall, 26 foods were consumed that contained phosphate additives in participants following the standard diet (14 patients) compared with 22 entries for those following the modified diet (12 patients).

The questions from the tolerance questionnaire are included in Figures 5 and 6. In all, 74% of participants following the standard diet and 66% of those following the new modified diet found the diet easy to follow ($P = 0.5$) (Figure 5). In all, 6% of participants following the standard diet and 34% of those following the modified diet reported an increase in bowel movements ($P = 0.008$) (Figure 5). On the modified diet, 81% of participants found it easy to include nuts, 44% found it easy to include pulses, and 52% found it easy to include egg whites in their diets (Figure 6).

**DISCUSSION**

Controlling phosphate load remains the primary goal in the treatment of hyperphosphatemia. In this study, we tested a modified phosphorus diet. The recommended changes to the national diet sheet summarized in Table 1 were based on a review of the literature and expert consensus. Due to concerns regarding hyperkalemia and dietary potassium intakes, there was caution in the magnitude of change recommended; for example, we recommended a limited amount of pulses and nuts and chose those with the lowest potassium contents, using pulses canned in water.

Neither dietary phosphorus intake nor serum phosphate were significantly different between the modified and standard diets. A possible explanation for the unchanged serum phosphate, is that the dietary change achieved was not of sufficient magnitude to reduce serum phosphate in our study population. We had anticipated that total phosphorus intake would not change because whereas avoiding excessive protein intake, avoiding additives, and reducing phosphorus-to-protein ratios would reduce total phosphorus intake, changing to plant-based proteins and choosing whole grains would increase total phosphorus intake. We were therefore dependent on reduced absorption from phytate-bound phosphorus to effect a change in serum levels. On the dialysis day, patients consumed on average 208 mg more phytate-bound phosphorus while following the modified diet. If we estimate a 30% lower absorption with phytate-bound phosphorus, then those following the modified diet may have absorbed only 62 mg less phosphorus. Second, the precision of these estimates is limited by the modest sample sizes, especially given the marked variability in serum phosphate levels. There is limited evidence that diabetes may affect phosphate handling, with 1 study in...
Table 4. Dietary outcome data from end of trial food diaries

| Variable                        | Standard diet (n = 30) | Modified diet (n = 30) | P value |
|---------------------------------|------------------------|------------------------|---------|
|                                | Mean ± SD (Min, max)   | Mean ± SD (Min, max)   |         |
| Dialysis day                    |                        |                        |         |
| Energy, kcal                    | 1620.6 ± 561.4 (647.4, 3056.2) | 1451.8 ± 379 (720.3, 2297.6) | 0.18    |
| Fiber, g                        | 14.6 ± 5.9 (3.9, 25.5) | 19.2 ± 6.6 (7.1, 34.7) | < 0.01  |
| Sodium, mg                      | 1579.5 ± 747.1 (647.4, 3399.1) | 1461 ± 661 (404.5, 3433.7) | 0.11    |
| Potassium, mg                   | 1834.9 ± 666.6 (426, 3129.6) | 1934.7 ± 700 (797, 3637.8) | 0.57    |
| Phosphorus, mg                  | 1012.1 ± 330.4 (207.9, 1584.9) | 1038.3 ± 337.9 (391.2, 1887) | 0.76    |
| Recommended protein intake, g   | 78.7 ± 7.57 (63, 94.8) | 74.26 ± 10.72 (63.9, 92.1) | 0.07    |
| Recorded protein intake, g      | 71.38 ± 26.44 (14.5, 120.4) | 65.79 ± 22.72 (19.3, 118.1) | 0.38    |
| ∆Protein, g                     | -7.31 ± 22.9 (-63.0, -33.7) | -8.48 ± 19.2 (-49.0, -49.3) | 0.83    |
| Potential renal acid load, mEq  | 20.4 ± 13.7 (-18.7, 43.8) | 16.7 ± 12.6 (-9.0, 53.2) | 0.27    |
| Nondialysis day                 |                        |                        |         |
| Energy, kcal                    | 1432.4 ± 534.8 (526.5, 2615.3) | 1388.7 ± 443.2 (744.9, 2300.6) | 0.73    |
| Fiber, g                        | 13.5 ± 6.1 (4.3, 32.4) | 18.3 ± 6.1 (5.7, 31.1) | < 0.01  |
| Sodium, mg                      | 1454.8 ± 731.6 (280.3, 4107.2) | 1285.5 ± 681.1 (524, 3526) | 0.38    |
| Potassium, mg                   | 1813.5 ± 806.3 (686.2, 2800.5) | 1923.8 ± 621.4 (1168.4, 3479.8) | 0.49    |
| Phosphorus, mg                  | 862.3 ± 328.2 (159.6, 1484.5) | 981.8 ± 387.6 (495.4, 2157.6) | 0.2     |
| Recommended protein intake, g   | 78.7 ± 7.57 (63, 94.8) | 74.26 ± 10.72 (63.9, 92.1) | 0.07    |
| Recorded protein intake, g      | 62.43 ± 24.27 (16.5, 120) | 64.62 ± 21.16 (26.3, 110.8) | 0.71    |
| ∆Protein, g                     | -18.3 ± 22.3 (-61.0, -35.8) | -9.64 ± 21.2 (-61.1, -33.2) | 0.24    |
| Potential renal acid load, mEq  | 13.3 ± 15.1 (-17.4, 44.8) | 15.3 ± 11.9 (-9.0, 54.5) | 0.57    |

*Estimates are given in grams (g) of difference between recorded protein intake minus the recommended protein intake.

chronic kidney disease (CKD) patients showing that phosphate loading more significantly affected serum phosphate in patients without diabetes.26 In our study, we had more diabetics in the modified arm, but the numbers in the trial would not support a subset analysis. Finally the blood samples were taken at various time points during the day and included both fasting and nonfasting samples, which may influence serum phosphate levels.27,28 Future trials should consider a larger sample size with longer follow-up and more uniform timing of samples.

Intakes of phytate-bound phosphorus were significantly higher in participants following the modified diet. This is important, because it indicates that patients did change their diets and that there was good separation between the 2 trial arms. Although the mean dietary potassium intake was higher in participants following the modified diet, the difference was not significant, and comparable serum potassium control was maintained across the 2 groups. The risk of hyperkalemia from increasing dietary potassium intake from whole grains and plant-based protein in ESKD needs further investigation.

Protein intakes were lower than recommended in both arms of the trial, but may be explained in part by underreporting. Such underreporting is common in dietary surveys,29–31 but is unlikely to be of a differential magnitude between our study arms, thus allowing us to compare the 2 diets. There are also concerns in the literature regarding the accuracy of phosphorus content in standard food tables, particularly in foods containing phosphate additives.32,33 As the level of consumption of foods containing phosphate additives in this study was low overall, this may not be a significant limitation.

Fiber intakes were significantly increased in the modified diet, although they were still not sufficient to meet general population recommendations. The increase in fiber intake is supported by the observation that patients’ bowel movements increased in those following the modified diet. This is clinically significant, because constipation has been reported in up to 72% of dialysis patients.34 An increase in fiber intake has also been shown to reduce levels of uremic toxins in CKD and ESKD.35,36 Uremic toxins may contribute to poorer outcomes.37–40 Although various interventions such as increasing fiber may alter the composition of intestinal microbiota in CKD and ESKD and reduce uremic toxins, clinical benefit is not yet confirmed.39,41

In this study, patients were encouraged to exchange 2 animal-based protein exchanges such as a 50-g meat portion for 2 plant-based protein exchanges such as 200g of pulses. The year 2016 was declared the International Year of the Pulse to heighten public awareness of the nutritional benefits of pulses,42 and these benefits may extend to the CKD population.43 Results from different studies seem to confirm a kidney-protective effect of plant-based diets,44–46 and recent reviews suggest that liberalizing the diet to allow plant foods may significantly improve the health and well-being of CKD and ESKD patients.47,48 There is also interest in the potential
benefit of phytate in the attenuation of cardiovascular risk in CKD populations, with a recent study demonstrating that an i.v. formulation of phytate significantly attenuated the progression of coronary artery calcium and aortic valve calcification in patients with ESKD receiving hemodialysis.

It has been reported that 55% of dialysis patients recalled “feeling deprived with dietary restrictions.” This modified diet introduced pulses, peas, and nuts as well as relaxed restrictions on whole grains. Increasing choice was a strong reason to guide adoption.

The strengths of our study are as follows. First, we tested a more liberalized plant-based diet in a multicenter RCT. Second, the intervention was tested in a hemodialysis population in whom hyperkalemia is more of a concern. Third, the study included dietary assessment using weighed diet records, providing valuable nutrient level information. Finally, this pragmatic trial was undertaken by registered dietitians who, with support from nephrologists, demonstrated the potential to carry out high-quality research at the front line. Limitations of this pilot study include its short duration and the modest sample size. Although 1 month allowed us to assess the short-term efficacy, safety, and tolerability, it did not allow us to assess the long-term effect and sustainability.

Figure 4. Density estimation of dietary intakes of phytate-bound phosphorus and total phosphorus. The density plot shows the distribution according to food diary entries on (a and c) the dialysis day and (b and d) the nondialysis day. Food diary entries were coded as containing or not containing a significant source of phytate, allowing calculation of both the daily intake of phytate-bound phosphorus and total phosphorus consumed per day.

Figure 5. Tolerance data. Participants were asked about their bowel movements and ease of following the information, and were asked to give a rating between 1 and 5.
As renal health care professionals, our discussions have focused on nutrient-based recommendations: for example, high protein, low phosphorus, low potassium, and low salt. The role of the renal dietitian has always been to translate multiple nutrient restrictions into individualized, practical, food-based recommendations. The dietitian aims to achieve this within a balanced healthy diet while maintaining quality of life. This is a complicated and evolving science and one that requires significant research. In this trial, we tested food-based recommendations, individualized to meet each patient’s requirements. Although the focus was only on phosphorus, all other nutrient restrictions were considered and incorporated into the prescribed diet.

Recently, nutrition science has been moving toward dietary patterns or food-based recommendations, with dietary patterns such as the Mediterranean diet and the new Nordic diet gaining credence in people with kidney disease. Dietary patterns may be more predictive of disease risk than individual foods or nutrients. We eat food, not nutrients, and, as demonstrated by dietary phosphorus that is phytate bound, the matrix in which food is digested has a huge bearing on absorption. Educating patients in using dietary patterns such as the Mediterranean diet pyramid may be an adequate dietary management strategy in the earlier stages of CKD; however, in the later stages of CKD and ESKD, the prescribed dietary pattern will need to be more carefully individualized because of concerns regarding intakes of specific nutrients (in particular, potassium) and because of the need to individualize protein requirement based on the patient’s stage of disease and treatment prescribed. The suggested changes, tested at trial, move our recommended renal diet closer to the Mediterranean dietary pattern while retaining the ability to individualize nutrient restrictions.

Clinical Practice Guidelines for Nutrition in CKD, which are being jointly undertaken by National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) in collaboration with the US Academy of Nutrition and Dietetics, are due for publication in 2020. These nutrient-based guidelines should be translated into food-based recommendations like our individualized diet plan and tested in an RCT trial. Undertaking these trials is undoubtedly challenging, but is absolutely essential to demonstrate the effectiveness of dietary interventions and to improve dietary strategies in CKD and ESKD. Research in dialysis patients is particularly important because of concerns regarding hyperkalemia. Although this advice may need to be used more cautiously in hyperkalemic patients, our study in a dialysis population provides an important first step toward safely reducing restrictions and exploring the effect of a specific dietary pattern on biochemical parameters and tolerance. The current study shows the feasibility of conducting a large-scale, longer-duration trial to demonstrate the efficacy of dietary intervention.

DISCLOSURE
All the authors declared no competing interests.

ACKNOWLEDGMENTS
The trial was registered at ClinicalTrials.gov: NCT03146923. We would like to acknowledge the Renal Interest Group of the Irish Nutrition and Dietetic Institute and the HRB CRF-C for funding the food samples for patients, the food scales, shopping cards, and NALA review. We would like to thank the Health Research Board Clinical Research Facility Cork (HRB CRF-C) for training support and for funding the FGF23 analysis and Alison Chipchase and William Fraser from the Norfolk and Norwich University Hospitals NHS Foundation

Figure 6. Tolerance data. Participants following the modified diet were ask about the ease of including new foods such as nuts, pulses, and egg whites and about how restrictive it was to avoid all foods with additives, and were asked to give a rating between 1 and 5.
Trust who performed the c terminal FGF23 assays. We would also like to acknowledge Dr. Carol Ni Chaoimh, School of Food and Nutritional Sciences, who provided assistance and training for dietary intake assessment. This study was undertaken as part of the PhD work for FB, who would like to acknowledge and thank her supervisors Dr. Frances Shiely, Professor Joe Eustace, Professor Mairead Kiely, and Professor Patricia Kearney.

SUPPLEMENTARY MATERIAL

CONSORT Checklist.

REFERENCES

1. KDIGO. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59.
2. Barreto FC, Barreto DV, Massy ZA, Drieue TB. Strategies for phosphate control in patients with CKD. Kidney Int Rep. 2019;4:1043–1056.
3. Adema AY, de Borst MH, ter Wee PM, Vervloet MG. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease. J Renal Nutr. 2014;24:143–150.
4. Gutiérrez OM, Wolf M. Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies. Semin Dial. 2010;23:401–406.
5. Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease. N Engl J Med. 2017;377:1765–1776.
6. Itkonen S, Karp H, Lamberg-Allardt C. Bioavailability of phosphorus. In: Urbarji J, Calvo MS, eds. Diet Phosphorus Health Nutr Regul Aspects. Boca Raton: CRC Press; 2018:221–233.
7. Clegg DJ, Hill Gallant KM. Plant-based diets in CKD. Clin J Am Soc Nephrol. 2019;14:141–143.
8. St-Jules DE, Goldfarb DS, Popp CJ, et al. Managing protein-energy wasting in hemodialysis patients: a comparison of animal- and plant-based protein foods. Semin Dial. 2019;32:41–46.
9. Moorthi RN, Armstrong CL, Janda K, et al. The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease. Am J Nephrol. 2014;40:582–591.
10. Moe SM, Zidehsarai MP, Chambers MA, et al. Vegetarian compared with meat dietary protein source and phosphorus homestasis in chronic kidney disease. Clinical J Am Soc Nephrol. 2011;8:257–264.
11. Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease. JAMA. 2009;301:629–635.
12. Byrne FN. The Effect of Eating Patterns on Nutritional Status and Phosphate Control in Haemodialysis Patients [Masters Thesis Research]. Cork: Department of Food and Nutritional Sciences, The National University of Ireland Cork; 2003.
13. St-Jules DE, Woolf K, Pompeii ML, et al. Reexamining the phosphorus-protein dilemma: does phosphorus restriction compromise protein status? J Renal Nutr. 2016;26:136–140.
14. Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88:1511–1518.
15. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–207.
16. Renal Interest Group of Irish Nutrition & Dietetic Institute. Eating Well With Kidney Disease. Dublin. 2010. Available at: www.indi.ie. Accessed October 16, 2020.
17. Byrne FN, Gillman B, Kiely M, et al. Revising dietary phosphorus advice in chronic kidney disease G3-5D. J Renal Nutr. 2020.
18. Byrne FN, Gillman B, Kiely M, et al. Translation of nutrient level recommendations to control serum phosphate into food-based advice. J Renal Nutr. 2020.
19. Harrington KE, Robson PJ, Kiely M, et al. The North/South Ireland Food Consumption Survey: survey design and methodology. Public Health Nutr. 2001;4:1037–1042.
20. Nutritics Software. Version Research Edition v5.028. Dublin: 2017. Available at: www.nutritics.com. Accessed October 16, 2020.
21. Public Health England. McCance and Widdowson’s Composition of Foods Integrated Dataset. London: Available at: https://www.gov.uk/government/publications/composition-of-foods-integrated-dataset-codif. Accessed February 1, 2018, 2015.
22. United States Department of Agriculture. USDA Food Composition Databases. Available at: https://ndb.nal.usda.gov/. Accessed February 1, 2018. 2017.
23. Black LJ, Ireland J, Møller A, et al. Development of an on-line Irish food composition database for nutrients. J Food Comp Anal. 2011;24:1017–1023.
24. Ritter CS, Slatopolsky E. Phosphate toxicity in CKD: the killer among us. Clin J Am Soc Nephrol. 2016;11:1088–1100.
25. St-Jules DE, Jaganathan R, Gutekunst L, et al. Examining the proportion of dietary phosphorus from plants, animals, and food additives excreted in urine. J Renal Nutr. 2017;27:78–83.
26. Muras K, Masajtis-Zagajewska A, Nowicki M. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease. J Clin Endocrinol Metab. 2013;98:E1901–E1908.
27. Portale AA, Halloran BP, Morris RC Jr. Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest. 1987;80:1147–1154.
28. Mazzetti T, Hopman WM, Couture L, et al. Phosphorus consumption within 1 hour prior to blood work and associated serum levels of phosphate, calcium, and PTH in adult patients receiving hemodialysis treatment. Can J Kidney Health Dis. 2019;6:2054358119856891.
29. Murakami K, Livingstone MBE. Prevalence and characteristics of misreporting of energy intake in US adults: NHANES 2003–2012. Br J Nutr. 2015;114:1294–1303.
30. Gibson R, Eriksen R, Lamb K, et al. Dietary assessment of British police force employees: a description of diet record coding procedures and cross-sectional evaluation of dietary energy intake reporting (The Airwave Health Monitoring Study). BMJ Open. 2017;7:e012927.
31. Black AE. Critical evaluation of energy intake using the Goldberg cut-off for energy intake: basal metabolic rate. A practical guide to its calculation, use and limitations. *Int J Obes.* 2000;24:1119.

32. Hannah J, Roe M, Warthon-Medina M, et al. Phosphorus in food: limitations of food composition data. *J Kidney Care.* 2018;3:362–367.

33. Calvo MS, Sherman RA, Uribarri J. Dietary phosphate and the forgotten kidney patient: a critical need for FDA regulatory action. *Am J Kidney Dis.* 2019;73:542–551.

34. Zuvela J, Trimmingham C, Le Leu R, et al. Gastrointestinal symptoms in patients receiving dialysis: a systematic review. *Nephrology (Carlton).* 2018;23:718–727.

35. Salmean YA, Segal MS, Palii SP, Dahl WJ. Fiber supplementation lowers plasma p-cresol in chronic kidney disease patients. *J Renal Nutr.* 2015;25:316–320.

36. Sirich TL, Plummer NS, Gardner CD, et al. Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. *Clin J Am Soc Nephrol.* 2014;9:1603–1610.

37. Krishnamurthy VM, Wei G, Baird BC, et al. High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. *Kidney Int.* 2012;81:300–306.

38. Evenepoel P, Meijers BK. Dietary fiber and protein: nutritional therapy in chronic kidney disease and beyond. *Kidney Int.* 2012;81:227–229.

39. Jovanovich A, Isakova T, Stubbs J. Microbiome and cardiovascular disease in CKD. *Clin J Am Soc Nephrol.* 2018;13:1598–1604.

40. Vanholder R, Schepers E, Pletinck A, et al. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. *J Am Soc Nephrol.* 2014;25:1897–1907.

41. Sumida K, Yamagata K, Kovesdy CP. Constipation in CKD. *Kidney Int.* 2012;81:279.

42. Byrne FN, Calvo MS. Pulses and chronic kidney disease: potential health benefits from a once forbidden food. In: Dahl WJ, ed. *Health Benefit of Pulses.* Switzerland: Springer; 2019:73–90.

43. Byrne FN, Calvo MS. Pulses and chronic kidney disease: potential health benefits from a once forbidden food. *Clin J Am Soc Nephrol.* 2019. C.JN.12391018.

44. Kim H, Caulfield LE, Garcia-Larsen V, et al. Plant-based diets and incident CKD and kidney function. *Clin J Am Soc Nephrol.* 2019;14:1907–1918.

45. Chauveau P, Koppe L, Combe C, et al. Vegetarian diets and chronic kidney disease. *Nephrol Dial Transplant.* 2019;34:199–207.

46. Patel KP, Luo FJ, Plummer NS, et al. The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. *Clin J Am Soc Nephrol.* 2012;7:982–988.

47. Chauveau P. Nutrition in chronic kidney disease: Nephrology Dialysis Transplantation notable advances in 2018. *Nephrol Dial Transplant.* 2019;34:893–896.

48. Buades Fuster JM, Sanchis Cortes P, Perelló Bestard J, Grases Freixedas F. Plant phosphates, phytate and pathological calcifications in chronic kidney disease. *Nefrología (English Edition).* 2017;37:20–28.

49. Raggi P, Bellasi A, Bushinsky D, et al. Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis. *Circulation.* 2020;141:728–739.

50. St-Jules DE, Woolf K, Pompeii ML, Sevick MA. Exploring problems in following the hemodialysis diet and their relationship to energy and nutrient intakes: the BalanceWise Study. *J Renal Nutr.* 2016;26:118–124.

51. St-Jules DE, Goldfarb DS, Pompeii ML, et al. Assessment and misassessment of potassium, phosphorus, and protein in the hemodialysis diet. *Semin Dial.* 2018;31:479–486.

52. Scialla JJ, Lin P-H. Revamping the ‘renal’ diet: using foods to control phosphorus physiology. *Nephrol Dial Transplant.* 2019;34:1619–1622.

53. Kelly JT, Palmer SC, Wai SN, et al. Healthy dietary patterns and risk of mortality and ESRD in CKD: a meta-analysis of cohort studies. *Clin J Am Soc Nephrol.* 2017;12:272–279.

54. Chauveau P, Aparicio M, Bellizzi V, et al. Mediterranean diet as the diet of choice for patients with chronic kidney disease. *Nephrol Dial Transplant.* 2018;33:725–735.

55. Hu FB. Dietary pattern analysis: a new direction in nutritional epidemiology. *Curr Opin Lipidol.* 2002;13:3–8.

56. Fundacion Dieta Mediterranea. Mediterranean Diet Pyramid. Available at: https://dietamediterranea.com/en/nutrition/. 2010. Accessed October 31, 2019.

57. Isakova T, Gutiérrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. *Kidney Int.* 2009;76:705–716.

58. Kalantar-Zadeh K, Tortorici AR, Chen JLT, et al. Dietary restrictions in dialysis patients: is there anything left to eat? *Semin Dial.* 2015;28:159–168.